tldrdailynews.com logo

Lilly Expands Genetic Medicines Portfolio with Beam's Opt-In Rights Acquisition

1 min read
Source: Endpoints News
Lilly Expands Genetic Medicines Portfolio with Beam's Opt-In Rights Acquisition
Photo: Endpoints News
TL;DR

Eli Lilly is acquiring Beam Therapeutics' opt-in rights to co-develop and co-commercialize Verve Therapeutics' base editing treatments in the cardiovascular disease space. This move is part of Lilly's ongoing efforts to strengthen its research in genetic medicines, following its previous $60 million upfront payment to Verve for a preclinical-stage program targeting lipoprotein(a).

Topics:businesspharmaceuticals#beam-therapeutics#cardiovascular-disease#eli-lilly#genetic-medicines#pharmaceuticals#verve-therapeutics
Share this article
  1. Lilly makes another move for Verve's genetic medicines, this time buying Beam's opt-in rights  Endpoints News
  2. Beam offloads Verve rights to Lilly for up to $600M  FierceBiotech
  3. Eli Lilly to pay $200 million for Beam's share of drugs from gene-editing firm Verve  STAT
  4. Eli Lilly inks gene editing deal with Beam (NYSE:LLY)  Seeking Alpha
  5. View Full Coverage on Google News

Want the full story? Read the original reporting

Read on Endpoints News